Book a Meeting

Non-fucosylated Anti-Human IL-5 (Mepolizumab) Therapeutic Antibody (CAT#: BioBet-018ZP) Datasheet

Target
IL-5
Isotype
IgG
Description
ADCC-enhanced Mepolizumab is a non-fucosylated anti-IL-5 therapeutic biobetter antibody.
Indication
Severe Eosinophilic Asthma
Severe nasal polyposis
Adult patients with eosinophilic granulomatosis
Classification
Therapeutic antibody; biobetter

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced IL-5 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
IL5
Full Name
interleukin 5
Background
This gene encodes a cytokine that acts as a growth and differentiation factor for both B cells and eosinophils. The encoded cytokine plays a major role in the regulation of eosinophil formation, maturation, recruitment and survival. The increased production of this cytokine may be related to pathogenesis of eosinophil-dependent inflammatory diseases. This cytokine functions by binding to its receptor, which is a heterodimer, whose beta subunit is shared with the receptors for interleukine 3 (IL3) and colony stimulating factor 2 (CSF2/GM-CSF). This gene is located on chromosome 5 within a cytokine gene cluster which includes interleukin 4 (IL4), interleukin 13 (IL13), and CSF2 . This gene, IL4, and IL13 may be regulated coordinately by long-range regulatory elements spread over 120 kilobases on chromosome 5q31
Alternative Names
EDF; TRF; IL-5
Gene ID
UniProt ID
Cellular Localization
Extracellular region or secreted
Involvement in Disease
Diseases associated with IL5 include Pulmonary Eosinophilia and Chronic Eosinophilic Pneumonia.
Related Pathways
Its related pathways are RET signaling and Signaling by GPCR.
Function
Factor that induces terminal differentiation of late-developing B-cells to immunoglobulin secreting cells.
Post-translational modifications
1. Glycosylation at Thr22 and Asn47 2. Modification sites at PhosphoSitePlus
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG
Antibody Clone
Mepolizumab
Host
Human
Species Reactivity
Human
Description
Mepolizumab is a humanized monoclonal antibody that specifically recognizes and blocks interleukin 5 (IL-5).
Indication
Severe Eosinophilic Asthma
Severe nasal polyposis
Adult patients with eosinophilic granulomatosis
Synonyms
Mepolizumab

Mepolizumab is an immunoglobulin G1κ monoclonal antibody that specifically targets the IL-5 antigen. IL-5 is a transmembrane glycoprotein with many functions and is highly expressed in hematological malignancies, including multiple myeloma tumors. IL-5 can regulate receptor-mediated adhesion, signaling, and cyclase and hydrolase activity. Mepolizumab inhibits tumor cell growth and induces broad-spectrum apoptosis by binding to IL-5 in a variety of mechanisms: Fc-mediated cross-linking, complement-dependent cytotoxicity, antibody-dependent cytotoxicity, and immune-dependent cell phagocytosis Lead tumor cell lysis.

Severe Eosinophilic Asthma
Severe nasal polyposis
Adult patients with eosinophilic granulomatosis

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK

Germany